Applications of Ethyl 5-Methyl-3-(Methylthio)-4,4-Dioxo-4,5-Dihydro-4Lambda6-Benzo[C]Thieno[3,4-E][1,2]Thiazine-1-Carboxylate in Industrial Manufacturing

We manufacture Ethyl 5-Methyl-3-(Methylthio)-4,4-Dioxo-4,5-Dihydro-4Lambda6-Benzo[C]Thieno[3,4-E][1,2]Thiazine-1-Carboxylate under strict quality systems to ensure full downstream traceability. Below we detail principal industrial application sectors, showing real-world use cases including integration routes, blending levels, compliance frameworks, and end-product types.

1. Advanced Pharmaceutical Intermediates for Sulfonylurea Drug Synthesis

In the pharmaceutical sector, our product functions as a key intermediate in the multi-stage synthesis of specific sulfonylurea drugs. Medicinal chemists use it in the creation of anti-diabetic APIs, engaging proprietary acylation and cyclization phases followed by stringent purification. Its compatibility with high-purity solvent systems and ability to tolerate specific synthesis temperatures prove crucial for downstream process yield and cost control. Strict adherence to impurity profile limits supports compliance documentation during regulatory submissions.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) reference for process impurities
• European Pharmacopoeia monograph guidelines for intermediates
• China Pharmacopoeia 2020 heavy metals specification

Typical usage ratio

• 0.8–1.3 molar equivalents per API batch, determined by stoichiometric pathway and side product control
• Adjustment based on yield optimization strategies

Downstream process integration

• Introduced at the nucleophilic substitution stage after initial heterocycle assembly
• Processed via liquid-liquid extraction and micronization prior to final coupling
• Subjected to in-process analytical verification using HPLC and NMR

Final product types

• Active pharmaceutical ingredients for second-generation sulfonylurea tablets
• Bulk intermediates for generic diabetes drug synthesis

2. Agrochemical Synthesis: Selective Herbicide Core Intermediate

Major agrochemical formulators use this thiazine-carboxylate structure as a foundational building block in the synthesis of triazine-based selective herbicides. Its sulfur and ester functionalities facilitate specific coupling and oxidation reactions required for active compound assembly. Process engineers optimize inclusion rates according to application timing, target weed spectrum, and field stability requirements while maintaining single-digit ppm levels of by-product residues to conform to regional registration dossiers.

Industry compliance standards

• ISO 9001:2015 Certified Quality Management System for agrochemical raw materials
• FAO/WHO CODEX guidelines for pesticide residue limits
• Regulation (EC) No 1107/2009 for crop protection product approval
• Chinese GB2763-2023 Maximum residue limits for pesticides

Typical usage ratio

• 8–12% w/w of total precursor blend in triazine herbicide synthesis
• Fine-tuning based on actives’ required field persistence and targeted crop species

Downstream process integration

• Added at oxidative coupling step post-benzo-thiophene ring formation
• Blended with base and oxidants in jacketed reactors for controlled conversion
• Transferred through multi-stage filtration to remove trace organosulfur residues

Final product types

• Pre-emergent and post-emergent triazine herbicide technicals
• EC (emulsifiable concentrate) and SC (suspension concentrate) crop protection formulations

3. Specialty Chemicals for High-Performance Polymer Additives

Producers of engineering plastics and high-durability coatings exploit this molecule as a reactive intermediate in modified thiazine-based polymer additives. Its stable heterocyclic core and functional ester group react with polyol or diamine co-monomers, imparting UV resistance, anti-aging, and improved processability to the finished materials. Quality teams conduct thorough residue tracking to assure compatibility with thermal compounding and extrusion processes.

Industry compliance standards

• REACH EC 1907/2006 Registration for polymer additives
• OECD Test Guideline 407 for chemical safety assessment
• RoHS 2011/65/EU for use in electrical and electronic polymer components
• UL 746C for polymeric materials used in electrical devices

Typical usage ratio

• 0.5–1.2% by weight of total masterbatch, dependent on end-use anti-degradation requirements
• Optimization based on target mechanical and thermal property retention

Downstream process integration

• Pre-mixed in solvent phase or dry-blended with base polymer prior to melt mixing
• Reacted during twin-screw extrusion with temperature profiles tailored to avoid decomposition
• Residuals monitored by GC-MS in finished granules or films

Final product types

• Automotive interior polymers with UV-stabilizer protection
• Industrial coating resins for outdoor applications
• Electrical insulator housings for switchgear assemblies

4. Fine Chemical Intermediate for Analytical Reagents Production

Laboratory reagent suppliers incorporate this substance in the stepwise assembly of custom analytical stains and chromogenic probes. Its functional groups allow controlled derivatization, enabling selective detection chemistries for use in high-sensitivity testing. Technicians select reaction conditions and inclusion levels based on strict batch-to-batch reproducibility and downstream purity requirements demanded by high-precision instrumentation users.

Industry compliance standards

• ISO 17034 Reference Material Producer accreditation
• ASTM D6299 Statistical Quality Assurance for analytical reagents
• US EPA Guidelines for Chemical Testing Laboratories
• CLSI GP38 Standard for preparation of reference materials in clinical labs

Typical usage ratio

• 0.05–0.2 molar equivalents per derivatization protocol, adjusted based on target chromophore absorption range
• Controlled at ppm scale in formulation of ultra-pure diagnostic kits

Downstream process integration

• Participates in functionalization steps with diazotization or sulfonation agents
• Undergoes filtration, crystallization, and lyophilization prior to analytical validation
• QC protocols deploy HPLC and FTIR for intermediate identification

Final product types

• Colorimetric reagent solutions for laboratory analysis
• Chromogenic diagnostic kits for clinical and environmental testing

5. Intermediate for Veterinary Drug Manufacturing

Our compound serves as a controlled input in the synthesis of veterinary active ingredients classified under sulfonamide derivatives. Manufacturers rely on its high lot-to-lot purity and traceability during sequenced alkylation and reduction reactions. Process scientists tailor raw material addition profiles to correspond to desired impurity thresholds and validated animal pharmaceutical specifications. Stringent tracking supports VMP (veterinary medicinal product) registration filings in multiple jurisdictions.

Industry compliance standards

• EU Regulation 2019/6 Veterinary Medicinal Products
• VICH GL3 Good Manufacturing Practice for APIs used in veterinary applications
• Japan PMDA Veterinary Drug standards
• Chinese Veterinary Drug Administration Law (2020 Revision)

Typical usage ratio

• 1.0–1.5 molar equivalents per target intermediate, varying with batch scale and impurity carryover risk
• Adjusted to meet pharmacopeial release criteria for residual solvents and heavy metals

Downstream process integration

• Introduced during nucleophilic acylation after initial thiazine ring assembly
• Subjected to step-wise extraction, solvent recovery, and vacuum drying
• Intermediate samples undergo GC analysis before use in subsequent veterinary API steps

Final product types

• Bulk veterinary active ingredient for therapeutic tablets and feed additives
• Sterile intermediates for injectable veterinary preparations